Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 2/20 | 0.42 |
| ▸ | CDC25A | P30304 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10451411 | 0.79 | CNR2 (0.50) | — | |
| SCHEMBL2892202 | 0.79 | CNR2 (0.50) | — | |
| SCHEMBL12235859 | 0.78 | ALDH1A1 (0.73) | ALDH1A1KDM4EHPGDHSD17B10KMT2A | |
| SCHEMBL22080751 | 0.77 | ALDH1A1 (0.60) | ALDH1A1KDM4EHPGDHSD17B10KMT2A | |
| SCHEMBL14560519 | 0.76 | HSD17B10 (0.62) | ALDH1A1KDM4EHSD17B10KMT2AMAPK1 | |
| SCHEMBL145135 | 0.76 | ALDH1A1 (0.60) | ALDH1A1KDM4EHPGDHSD17B10KMT2A | |
| SCHEMBL10451307 | 0.76 | ACHE (0.49) | ALDH1A1KDM4EHPGDKMT2AMEN1 | |
| SCHEMBL12979075 | 0.76 | ALDH1A1 (0.60) | ALDH1A1KDM4EHPGDHSD17B10KMT2A | |
| SCHEMBL2665904 | 0.75 | CHRM2 (0.64) | KDM4ECHRM2 | |
| SCHEMBL23731163 | 0.74 | CES1 (0.68) | ALDH1A1KMT2AMEN1CHRM2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362234-B2 | Solid support reagents for synthesis | ARCHEMIX LLC | 2013-01-29 | — | — | US | disclosed |
| US-20100041866-A1 | Solid Support Reagents for Synthesis | ARCHEMIX CORP. (US) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041866-A1 | Solid Support Reagents for Synthesis | C1R, CBR1, CBR3 | ALDH1A1 2676/4885KDM4E 1835/4885HPGD 2784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.